Enhanced combination synergy: Significant anti-tumor synergy was observed with APR-1051 and anti-PD-1 therapies in HPV+ HNSCC models, positioning APR-1051 as a candidate for combination-based ...

Preclinical and clinical data show promise for APR-1051 in treating HPV+ head and neck cancer, highlighting efficacy and safety. Quiver AI Summary Aprea Therapeutics announced promising ...

Given WEE1’s central role in regulating the G2/M checkpoint, HPV+ tumor cells appear highly reliant on WEE1 signaling for survival. This provides a biomarker driven strategy for targeted patient ...

Potent single-agent activity: APR-1051 demonstrated robust antiproliferative effects across a broad panel of human and murine head and neck cancer cell lines, including HPV+ subtypes, with IC50 ...

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 ...

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 ...

HPV-driven cancers, including HPV+ HNSCC, are particularly susceptible to this treatment due to defects in their DNA damage repair pathways. Aprea is focusing on identifying patient populations ...

Aprea Therapeutics (APRE) announced that a patient with HPV+ head and neck squamous cell carcinoma, HNSCC, has been dosed in the ongoing ACESOT-1051 clinical trial evaluating APR-1051.

ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 ...

Aprea recently entered into a Material Transfer Agreement (MTA) with MD Anderson to support preclinical research aimed at exploring the potential of APR-1051 in treating HPV+ and HPV- head and neck ...

Aprea recently entered into a Material Transfer Agreement (MTA) with MD Anderson to support preclinical research aimed at exploring the potential of APR-1051 in treating HPV+ and HPV- head and ...